Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Double-blind, Double-dummy, Placebo-controlled, 5-period, Crossover Study Assessing the Effects of Rapastinel Compared to Alprazolam, Ketamine, and Placebo on Simulated Driving Performance in Normal Healthy Participants

NCT03814733 is registered in ClinicalTrials.gov with Naurex, Inc, an affiliate of Allergan plc as lead sponsor.

NCT NCT03814733
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03814733 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Double-blind, Double-dummy, Placebo-controlled, 5-period, Crossover Study Assessing the Effects of Rapastinel Compared to Alprazolam, Ketamine, and Placebo on Simulated Driving Performance in Normal Healthy Participants
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Phase
Phase 1
Overall status
Completed
Start date
November 5, 2018
Completion date
April 3, 2019
Enrollment
107 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

driving performance